Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$1.29
+2.0%
$1.69
$1.19
$23.70
$9.89M5.65285,819 shs83,258 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
$13.00
$10.58M2.352,472 shsN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
$4.58
-1.3%
$8.58
$4.50
$108.00
$2.34M0.51146,635 shs14,450 shs
Talphera, Inc. stock logo
TLPH
Talphera
$0.85
-0.4%
$0.48
$0.38
$1.19
$17.44M-0.16981,652 shs571,166 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
+2.02%-5.60%-25.59%-46.79%-94.56%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
-0.22%-6.64%-38.13%-59.30%-79.51%
Talphera, Inc. stock logo
TLPH
Talphera
+4.15%+57.96%+108.30%+66.28%-17.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$1.29
+2.0%
$1.69
$1.19
$23.70
$9.89M5.65285,819 shs83,258 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
$13.00
$10.58M2.352,472 shsN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
$4.58
-1.3%
$8.58
$4.50
$108.00
$2.34M0.51146,635 shs14,450 shs
Talphera, Inc. stock logo
TLPH
Talphera
$0.85
-0.4%
$0.48
$0.38
$1.19
$17.44M-0.16981,652 shs571,166 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
+2.02%-5.60%-25.59%-46.79%-94.56%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
-0.22%-6.64%-38.13%-59.30%-79.51%
Talphera, Inc. stock logo
TLPH
Talphera
+4.15%+57.96%+108.30%+66.28%-17.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
0.00
N/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00
N/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
0.00
N/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
3.50
Strong Buy$5.00501.68% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
$580K17.32N/AN/A$0.50 per share2.62
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
N/AN/AN/AN/A$14.31 per shareN/A
Talphera, Inc. stock logo
TLPH
Talphera
$650K26.23N/AN/A$0.47 per share1.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
-$44.54M-$8.31N/AN/A-7,652.75%N/A-682.08%11/10/2025 (Estimated)
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
-$240KN/A0.00N/AN/AN/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
-$5.58M-$43.48N/AN/AN/A-556.47%-192.35%11/12/2025 (Estimated)
Talphera, Inc. stock logo
TLPH
Talphera
-$13M-$0.40N/AN/AN/AN/A-152.38%-64.32%11/12/2025 (Estimated)

Latest SLRX, TLPH, ERNA, and PHXM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Talphera, Inc. stock logo
TLPH
Talphera
-$0.1150-$0.10+$0.0150-$0.10N/AN/A
8/13/2025Q2 2025
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A-$0.61N/A-$0.61N/AN/A
8/12/2025Q2 2025
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
-$33.00-$0.45+$32.55-$0.45N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
N/AN/AN/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
N/A
1.81
1.81
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.23
1.78
N/A
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
N/A
0.61
0.61
Talphera, Inc. stock logo
TLPH
Talphera
N/A
2.93
2.93

Institutional Ownership

CompanyInstitutional Ownership
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
70.55%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.40%
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
11.88%
Talphera, Inc. stock logo
TLPH
Talphera
37.67%

Insider Ownership

CompanyInsider Ownership
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
4.49%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
1.94%
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
1.20%
Talphera, Inc. stock logo
TLPH
Talphera
3.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ernexa Therapeutics Inc. stock logo
ERNA
Ernexa Therapeutics
107.67 million7.33 millionNo Data
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
493.41 million3.35 millionNo Data
Salarius Pharmaceuticals, Inc. stock logo
SLRX
Salarius Pharmaceuticals
20510,000504,000Not Optionable
Talphera, Inc. stock logo
TLPH
Talphera
1920.52 million19.87 millionOptionable

Recent News About These Companies

Talphera, Inc. (NASDAQ:TLPH) Sees Significant Drop in Short Interest
CorMedix Announces Strategic Minority Investment in Talphera
Talphera Cuts Expenses 14 Percent
Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript
A Preview Of Talphera's Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ernexa Therapeutics stock logo

Ernexa Therapeutics NASDAQ:ERNA

$1.29 +0.03 (+1.98%)
Closing price 04:00 PM Eastern
Extended Trading
$1.29 0.00 (0.00%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

PHAXIAM Therapeutics stock logo

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)
As of 09/8/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Salarius Pharmaceuticals stock logo

Salarius Pharmaceuticals NASDAQ:SLRX

$4.58 -0.06 (-1.29%)
Closing price 04:00 PM Eastern
Extended Trading
$4.65 +0.07 (+1.53%)
As of 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Talphera stock logo

Talphera NASDAQ:TLPH

$0.85 0.00 (-0.35%)
Closing price 04:00 PM Eastern
Extended Trading
$0.83 -0.02 (-1.88%)
As of 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.